Skip to main content

Alecnib 150 mg ( Alectinib)

Alecnib 150 mg (Alectinib)

Introduction to Alecnib 150 mg

Alecnib 150 mg is identified as a product containing alectinib, a targeted anticancer medicine used in the treatment of certain patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Alectinib belongs to a group of medicines known as ALK tyrosine kinase inhibitors. These medicines target specific abnormal proteins involved in cancer-cell growth and survival.

The stated strength of Alecnib is 150 mg. Alectinib is an oral prescription medicine that is available in 150 mg capsules in its established reference formulation. The dosage form and product specifications of Alecnib itself should be confirmed against its original packaging.

Alectinib is the active ingredient in the established reference medicine Alecensa. The reference product is associated with Roche and Genentech in relevant markets. However, the manufacturer of Alecnib should not be assumed to be the same company without product-specific documentation.

This website provides educational information about Alecnib, alectinib, its therapeutic uses, mechanism of action, administration, safety considerations and clinical background.

What Is Alectinib?

Alectinib is a targeted anticancer medicine classified as an anaplastic lymphoma kinase inhibitor. It works by blocking the activity of abnormal ALK proteins that can contribute to the development and progression of certain lung cancers.

ALK is a gene that provides instructions for producing a protein involved in cellular signaling. In some patients with NSCLC, changes involving the ALK gene create abnormal fusion proteins. These proteins can send continuous growth signals, allowing cancer cells to multiply and survive.

Alectinib interferes with this abnormal signaling process. By inhibiting ALK activity, it can help control the growth of cancer cells that depend on this molecular pathway.

Unlike conventional chemotherapy, which can affect many rapidly dividing cells, targeted therapy is designed to interfere with particular molecular abnormalities associated with cancer. This makes identification of the relevant genetic alteration an important part of treatment selection.

Alectinib is not a general treatment for every type of lung cancer. Its use depends on confirming ALK positivity through an appropriate molecular diagnostic test.

What Is Alecnib 150 mg Used For?

Alectinib is used for specified adults with ALK-positive non-small cell lung cancer.

There are two important treatment settings in current U.S. prescribing information.

Adjuvant treatment after lung cancer surgery

Alectinib may be prescribed as adjuvant treatment for adults who have undergone surgical removal of qualifying ALK-positive NSCLC.

Adjuvant treatment refers to therapy given after the primary tumor has been removed. Although surgery may remove the visible cancer, microscopic cancer cells can remain in the body. These cells may contribute to recurrence.

Alectinib is indicated in the United States for qualifying patients whose resected tumors are at least 4 cm or involve lymph nodes and have confirmed ALK positivity.

For this indication, the reference-product prescribing information specifies treatment for a total of two years or until cancer recurrence or unacceptable toxicity, whichever occurs first.

Metastatic ALK-positive non-small cell lung cancer

Alectinib is also used to treat adults with ALK-positive metastatic NSCLC.

Metastatic lung cancer means that the disease has spread from its original location to other parts of the body. Treatment aims to control cancer growth, reduce disease progression and support disease management.

The choice of alectinib depends on molecular testing, previous treatment, the patient’s overall health and the applicable prescribing indication.

Treatment indications may differ between countries. Patients should therefore follow the regulatory information applicable to their location.

How Does Alectinib Work?

Alectinib works by inhibiting abnormal ALK tyrosine kinase activity.

In certain lung cancers, an abnormal genetic rearrangement creates an ALK fusion protein. This protein may remain continuously active and stimulate pathways responsible for cancer-cell growth and survival.

Alectinib binds to and inhibits the abnormal ALK protein, interfering with its signaling activity.

Its mechanism involves:

  • Inhibiting abnormal ALK kinase activity.

  • Blocking molecular signals that encourage cancer-cell growth.

  • Interfering with pathways involved in cancer-cell survival.

  • Helping control the progression of ALK-driven tumors.

  • Inhibiting additional kinase activity, including RET.

Alectinib can also penetrate the central nervous system. This characteristic is clinically relevant because ALK-positive lung cancer may spread to the brain.

However, individual responses differ. Alectinib cannot guarantee a particular treatment outcome, and ongoing clinical assessment is necessary.

Alecnib 150 mg Product Information

Product detail

Information

Brand name

Alecnib

Generic medicine

Alectinib

Stated strength

150 mg

Dosage form

To be confirmed from product packaging

Therapeutic class

ALK tyrosine kinase inhibitor

Medicine category

Targeted anticancer medicine

Main treatment area

ALK-positive NSCLC

Route of administration

Oral, subject to product verification

Reference brand

Alecensa

Reference-product company

Roche/Genentech

Alecnib manufacturer

Not independently verified

Regulatory status

–

The 150 mg strength refers to the stated quantity of active ingredient per dosage unit. It should not be confused with the total daily dose prescribed for an individual patient.

General Dosage and Administration

The established U.S. Alecensa prescribing regimen for adults is 600 mg twice daily with food. This corresponds to four 150 mg capsules per administration, or eight 150 mg capsules in total per day.

This information describes the reference medicine and must not automatically be treated as a prescription for Alecnib.

Alectinib is generally taken orally with food. Patients should follow their prescribed schedule and swallow the capsules whole.

Important administration principles include:

  • Take the medicine exactly as prescribed.

  • Take each scheduled dose with food.

  • Maintain a consistent morning and evening schedule.

  • Swallow capsules whole.

  • Do not open or dissolve the capsules.

  • Do not change the dose without medical guidance.

  • If vomiting occurs after a dose, do not take an additional replacement dose.

  • If a dose is missed, take the next dose at its scheduled time rather than doubling the dose.

Dose reductions or interruptions may be necessary when significant adverse reactions occur.

The appropriate dose and treatment schedule must be determined by a qualified healthcare professional.

Common Side Effects of Alectinib

Like other prescription anticancer medicines, alectinib can cause adverse reactions.

Commonly reported side effects include:

  • Constipation

  • Fatigue

  • Muscle pain

  • Swelling of the hands, feet or other body areas

  • Skin rash

  • Cough

  • Changes in liver enzyme levels

  • Increased bilirubin

  • Increased creatine phosphokinase levels

The severity of these effects varies between patients. Some reactions may improve with supportive treatment or medical dose adjustments.

Patients should inform their healthcare professional about persistent or worsening symptoms.

Serious Safety Warnings

Alectinib can cause serious adverse reactions requiring medical assessment.

Liver toxicity: Alectinib may cause liver injury. Liver-function tests should be performed before and during treatment. Yellowing of the skin, dark urine, unusual fatigue or persistent nausea should be reported.

Interstitial lung disease and pneumonitis: Inflammation of lung tissue can occur. New or worsening cough, fever or difficulty breathing requires prompt medical assessment.

Bradycardia: Alectinib may slow the heart rate. Dizziness, fainting, lightheadedness or unusual weakness should be reported.

Severe muscle toxicity: Muscle pain, tenderness and weakness can occur alongside increased creatine phosphokinase levels. Blood testing may be required.

Hemolytic anemia: Alectinib can cause premature destruction of red blood cells. Symptoms may include fatigue, jaundice, weakness and dark urine.

Kidney impairment: Severe kidney problems have been reported and require medical monitoring.

Severe hypertriglyceridemia and pancreatitis: Elevated blood triglycerides can occur and may contribute to inflammation of the pancreas. Monitoring may be necessary.

Embryo-fetal toxicity: Alectinib may harm an unborn baby. Pregnancy prevention should be discussed before treatment.

Breastfeeding is not recommended during treatment according to current U.S. reference-product prescribing information.

Clinical Monitoring During Treatment

Regular monitoring helps healthcare professionals identify adverse reactions and evaluate treatment safety.

Monitoring may include:

  • Liver enzymes and bilirubin.

  • Kidney function.

  • Heart rate and blood pressure.

  • Creatine phosphokinase levels.

  • Blood counts and signs of anemia.

  • Blood triglyceride levels.

  • Respiratory symptoms.

  • Pregnancy considerations where relevant.

The current U.S. reference-product label recommends liver laboratory testing every two weeks during the first three months, then monthly and as clinically indicated. CPK monitoring is also recommended every two weeks during the first month and when unexplained muscle symptoms occur.

The exact monitoring schedule depends on the patient’s condition and clinical treatment plan.

Manufacturer and Product Verification

Alecnib is the stated brand name, and alectinib is its stated active ingredient.

The established reference medicine is Alecensa. Roche and Genentech are associated with that reference product, but this does not establish the identity of the Alecnib manufacturer.

Before identifying the manufacturer or making claims about product authorization, the following information should be checked:

  • Original product packaging.

  • Manufacturer’s legal name.

  • Manufacturing location.

  • Brand ownership.

  • Marketing authorization holder.

  • Product registration information.

  • Batch or lot number.

  • Manufacturing and expiry dates.

  • Official product leaflet.

Product authenticity should be assessed through legitimate pharmaceutical supply channels and appropriate regulatory documentation.

Medical Disclaimer

The information presented on Alecnib.com is intended for general educational purposes. It does not replace professional medical advice, diagnosis or treatment.

Alectinib is a prescription anticancer medicine and should only be used under the supervision of a qualified healthcare professional.

Patients should not start, stop or modify treatment based solely on information found on this website. Any concerning symptoms or suspected serious adverse reactions should be discussed promptly with the treating medical team.

Conclusion

Alecnib 150 mg is identified as an alectinib-containing product intended for information about targeted treatment of ALK-positive non-small cell lung cancer.

Alectinib works by inhibiting abnormal ALK signaling, which can help control the growth and progression of cancer cells with the relevant genetic alteration. Its clinical use requires appropriate molecular testing, individualized prescribing and regular safety monitoring.

Michael Anderson
Clear and helpful product information. I found the explanations about alectinib, its uses, dosage information and important precautions easy to understand. The website provides useful information for people researching targeted cancer treatments.
Daniel Roberts
The information about Alecnib 150 mg is well organized and informative. I particularly appreciated the sections explaining ALK-positive lung cancer, how alectinib works and the importance of regular medical monitoring.
James Wilson
A useful website for learning about alectinib treatment. The details about possible side effects, precautions and frequently asked questions make the information easier to follow. I appreciate the clear presentation.

Latest News

No posts found.

FAQs

Alectinib is primarily used to treat specific patients with ALK-positive non-small cell lung cancer (NSCLC). This cancer contains an abnormal genetic alteration involving the ALK gene, which can contribute to uncontrolled cancer-cell growth.

Treatment eligibility depends on molecular testing, disease stage, previous treatment and the applicable prescribing information.

ALK inhibitors are targeted medicines designed to block abnormal signaling from ALK proteins in certain cancer cells. Other targeted cancer medicines act on different molecular targets, such as EGFR, HER2 or other signaling proteins.

The appropriate targeted treatment depends on the specific genetic characteristics of the tumor. Alectinib is intended for eligible patients with ALK-positive NSCLC.

Yes. Alectinib is an established first-line treatment option for eligible patients with advanced ALK-positive non-small cell lung cancer.

The oncology specialist considers molecular test results, disease stage, medical history and other clinical factors before selecting the treatment.

Some cancers may develop resistance during treatment, meaning that cancer cells begin growing despite the medicine. Resistance can occur because of additional genetic changes or other biological mechanisms.

If disease progression is suspected, the oncology team may recommend imaging, molecular testing or another clinical assessment. Further treatment decisions depend on the resistance mechanism and the patient's condition.

Some patients receiving alectinib may experience gastrointestinal symptoms, fatigue or other treatment-related effects that can influence appetite and eating habits.

Unexplained weight loss, persistent nausea or difficulty maintaining adequate nutrition should be discussed with the healthcare team. Nutritional support may help patients manage these problems during treatment.

Yes. Peripheral edema, which refers to fluid accumulation and swelling, can occur during alectinib treatment. It may affect the feet, ankles, hands or other areas.

Patients should report new or worsening swelling. Sudden swelling, chest discomfort or breathing difficulty requires prompt medical assessment because other medical conditions may also cause these symptoms.

Constipation is a reported side effect of alectinib. Patients may experience less frequent bowel movements, harder stools or difficulty passing stools.

Maintaining appropriate fluid intake, eating fiber-containing foods when suitable and remaining physically active may help. Persistent constipation, severe abdominal pain or vomiting should be discussed with a healthcare professional.

Alectinib can cause bradycardia, a condition in which the heart beats more slowly than normal. This may lead to dizziness, tiredness, weakness or fainting in some patients.

Healthcare professionals may assess heart rate and review other medicines that can slow the heart. Patients should report fainting, significant dizziness or unusual weakness promptly.

Older adults may receive alectinib when they meet the relevant treatment criteria. Age alone does not automatically determine whether the medicine is appropriate.

The oncology team considers overall health, liver and kidney function, heart rate, other medical conditions, current medicines and the patient's ability to tolerate treatment.

Patients with existing liver disease require careful assessment before receiving alectinib because the medicine can also cause liver injury.

The healthcare professional may review liver-function results, assess the severity of existing liver impairment and determine whether treatment or additional monitoring is appropriate. Patients should not begin treatment without specialist guidance.

Some patients can continue many normal daily activities during alectinib treatment, although fatigue, muscle pain, swelling or other adverse reactions may affect their activity levels.

Patients should adjust physical activity according to their condition and discuss suitable exercise with their healthcare team. Severe muscle pain or unusual weakness should be assessed rather than ignored.

Alectinib may cause symptoms such as fatigue, dizziness or a slow heart rate in some patients. These effects can make driving or operating machinery unsafe.

Patients should understand how the medicine affects them before performing activities requiring concentration and coordination. Anyone experiencing dizziness, faintness or significant tiredness should avoid driving and seek medical advice.

These numbers describe different amounts of the active ingredient. A 150 mg capsule contains 150 mg of alectinib, while 600 mg describes a total dose containing 600 mg of the active ingredient.

For the U.S. reference Alecensa capsule regimen, the usual adult dose is 600 mg twice daily with food. Four 150 mg capsules make up one 600 mg dose. This reference regimen is not an individualized dosing instruction for Alecnib.

Molecular testing identifies genetic alterations that may influence which cancer treatments are appropriate. For alectinib, testing is important because the medicine targets abnormal ALK signaling.

Without confirmation of an eligible ALK alteration, the healthcare team cannot establish that the patient meets the molecular criteria for this targeted treatment. Testing also helps distinguish ALK-positive disease from lung cancers driven by other molecular changes.

Caregivers can help patients maintain their prescribed treatment routine, attend medical appointments and follow laboratory monitoring schedules.

They can also help keep an updated list of medicines, observe changes in health and communicate concerning symptoms to the oncology team.

Caregivers should be familiar with important warning signs, including breathing difficulties, jaundice, fainting, severe muscle symptoms and unusual weakness. Suspected serious reactions require prompt medical assessment.